ArticleFrontiers in microbiology2026
Dynamic changes in IFI44L and SAMHD1 mRNA levels in PBMCs are associated with treatment response in HBeAg-negative chronic hepatitis B during peg-IFN-α therapy.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine whether IFI44L and SAMHD1 mRNA expression in peripheral blood mononuclear cells (PBMCs) is associated with treatment response and HBsAg clearance in patients with HBeAg-negative chronic hepatitis B (CHB) receiving pegylated interferon alpha (Peg-IFN-α). Methods: In this prospective cohort, HBeAg-negative patients with CHB received Peg-IFN-α for 48 weeks, with virological and serological responses assessed at week 48. Virological response (VR) or non-virological response (NVR) was defined according to serum HBV DNA, whereas serological response (SR) or non-serological response (NSR) was based on HBsAg loss. IFI44L and SAMHD1 mRNA levels in PBMCs collected at baseline and weeks 12 and 24 were quantified by quantitative real-time PCR. Correlation analyses were used to examine associations with changes in HBsAg and HBV DNA. Univariable and multivariable logistic regression analyses were conducted to identify factors independently associated with VR and SR, and receiver operating characteristic (ROC) curves were used to assess the discriminatory performance of the two genes. Results: Following 48 weeks of Peg-IFN-α treatment, 53.95% of patients achieved VR and 36.84% achieved SR. IFI44L and SAMHD1 expression showed distinct on-treatment patterns according to virological and serological outcomes. Higher expression of either gene at weeks 12 and 24 was associated with greater reductions in HBsAg and HBV DNA at the corresponding time points, and week 12 expression was also positively associated with the subsequent declines in both markers by week 24. In multivariable analyses, IFI44L and SAMHD1 expression at weeks 12 and 24 remained independently associated with VR and SR at week 48. ROC analysis showed greater discriminatory performance at the on-treatment assessment points, with the highest AUCs observed at week 24. At this time point, IFI44L yielded AUCs of 0.8822 for VR and 0.8445 for SR, while SAMHD1 yielded AUCs of 0.8627 and 0.8400, respectively. Conclusion: IFI44L and SAMHD1 may represent candidate dynamic on-treatment biomarkers of host interferon responsiveness during Peg-IFN-α therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.